Christine Walsh
Concepts (363)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 50 | 2024 | 563 | 8.270 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 6 | 2024 | 116 | 2.210 |
Why?
| | Neoplasms, Glandular and Epithelial | 12 | 2022 | 49 | 2.100 |
Why?
| | Endometrial Neoplasms | 11 | 2022 | 199 | 2.030 |
Why?
| | BRCA1 Protein | 8 | 2020 | 76 | 1.660 |
Why?
| | BRCA2 Protein | 8 | 2021 | 63 | 1.660 |
Why?
| | Genes, BRCA1 | 10 | 2023 | 38 | 1.390 |
Why?
| | Genes, BRCA2 | 9 | 2023 | 29 | 1.380 |
Why?
| | Peritoneal Neoplasms | 4 | 2018 | 94 | 1.230 |
Why?
| | Adenocarcinoma, Clear Cell | 4 | 2016 | 14 | 1.210 |
Why?
| | Cystadenocarcinoma, Serous | 9 | 2019 | 75 | 1.090 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1274 | 0.940 |
Why?
| | Maintenance Chemotherapy | 2 | 2024 | 35 | 0.920 |
Why?
| | Neoplasm Recurrence, Local | 13 | 2024 | 1055 | 0.870 |
Why?
| | Germ-Line Mutation | 6 | 2016 | 172 | 0.860 |
Why?
| | Indazoles | 2 | 2020 | 69 | 0.830 |
Why?
| | Bevacizumab | 2 | 2020 | 136 | 0.820 |
Why?
| | Neoplasm Staging | 14 | 2021 | 1373 | 0.810 |
Why?
| | Piperidines | 2 | 2020 | 205 | 0.760 |
Why?
| | Myeloproliferative Disorders | 1 | 2021 | 27 | 0.740 |
Why?
| | Sleep, REM | 2 | 2023 | 33 | 0.720 |
Why?
| | Polymorphism, Single Nucleotide | 15 | 2018 | 2190 | 0.690 |
Why?
| | Gray Matter | 1 | 2021 | 80 | 0.680 |
Why?
| | Phthalazines | 1 | 2020 | 45 | 0.680 |
Why?
| | Sleep Apnea Syndromes | 1 | 2021 | 89 | 0.670 |
Why?
| | Female | 75 | 2024 | 72840 | 0.670 |
Why?
| | Genetic Predisposition to Disease | 15 | 2023 | 2417 | 0.660 |
Why?
| | Deoxycytidine | 1 | 2021 | 175 | 0.660 |
Why?
| | Aged, 80 and over | 23 | 2021 | 7569 | 0.630 |
Why?
| | Cisplatin | 1 | 2021 | 318 | 0.620 |
Why?
| | Mutation | 14 | 2023 | 3953 | 0.620 |
Why?
| | Fallopian Tube Neoplasms | 2 | 2016 | 17 | 0.610 |
Why?
| | Genital Neoplasms, Female | 3 | 2018 | 88 | 0.610 |
Why?
| | White Matter | 2 | 2020 | 145 | 0.610 |
Why?
| | Piperazines | 2 | 2020 | 350 | 0.600 |
Why?
| | Medical Oncology | 2 | 2020 | 290 | 0.600 |
Why?
| | Molecular Targeted Therapy | 3 | 2017 | 413 | 0.600 |
Why?
| | Breast Neoplasms | 11 | 2023 | 2239 | 0.590 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2021 | 165 | 0.590 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 530 | 0.590 |
Why?
| | Genetic Testing | 3 | 2017 | 452 | 0.580 |
Why?
| | Gynecology | 1 | 2020 | 176 | 0.570 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 2129 | 0.540 |
Why?
| | Aged | 37 | 2021 | 23729 | 0.540 |
Why?
| | Thromboplastin | 1 | 2017 | 74 | 0.540 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 306 | 0.530 |
Why?
| | Humans | 81 | 2024 | 136783 | 0.520 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 35 | 0.510 |
Why?
| | DNA Repair-Deficiency Disorders | 1 | 2016 | 4 | 0.500 |
Why?
| | Digoxin | 1 | 2015 | 30 | 0.490 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 804 | 0.480 |
Why?
| | Venous Thrombosis | 1 | 2017 | 186 | 0.470 |
Why?
| | Carcinoma, Endometrioid | 2 | 2014 | 50 | 0.440 |
Why?
| | DNA-Binding Proteins | 3 | 2012 | 1500 | 0.440 |
Why?
| | Hysterectomy | 4 | 2009 | 128 | 0.430 |
Why?
| | Prognosis | 16 | 2022 | 4018 | 0.430 |
Why?
| | Organoplatinum Compounds | 2 | 2015 | 46 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1683 | 0.420 |
Why?
| | Middle Aged | 39 | 2021 | 33200 | 0.420 |
Why?
| | Survival Rate | 9 | 2021 | 1969 | 0.410 |
Why?
| | Cognition | 1 | 2020 | 1166 | 0.390 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 838 | 0.380 |
Why?
| | Loss of Heterozygosity | 2 | 2008 | 51 | 0.370 |
Why?
| | Nuclear Proteins | 4 | 2016 | 710 | 0.370 |
Why?
| | Cystadenocarcinoma, Papillary | 2 | 2008 | 5 | 0.370 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2011 | 12 | 0.360 |
Why?
| | Ovariectomy | 4 | 2023 | 151 | 0.350 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2014 | 57 | 0.340 |
Why?
| | Internship and Residency | 1 | 2020 | 1131 | 0.330 |
Why?
| | Alzheimer Disease | 3 | 2023 | 557 | 0.330 |
Why?
| | DNA, Neoplasm | 4 | 2014 | 164 | 0.330 |
Why?
| | DNA Repair | 1 | 2011 | 230 | 0.310 |
Why?
| | Venous Thromboembolism | 1 | 2013 | 309 | 0.310 |
Why?
| | Indoles | 2 | 2024 | 410 | 0.310 |
Why?
| | Platinum | 2 | 2021 | 49 | 0.310 |
Why?
| | Uniparental Disomy | 1 | 2008 | 9 | 0.300 |
Why?
| | Uterine Neoplasms | 4 | 2014 | 109 | 0.300 |
Why?
| | Transcription Factors | 4 | 2016 | 1714 | 0.290 |
Why?
| | Endonucleases | 1 | 2008 | 32 | 0.290 |
Why?
| | Adult | 31 | 2021 | 37616 | 0.290 |
Why?
| | Homologous Recombination | 2 | 2020 | 26 | 0.290 |
Why?
| | Disease-Free Survival | 5 | 2013 | 687 | 0.280 |
Why?
| | CA-125 Antigen | 2 | 2021 | 14 | 0.270 |
Why?
| | Risk Factors | 14 | 2023 | 10331 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 800 | 0.260 |
Why?
| | Neoplasms | 1 | 2021 | 2644 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 65 | 0.250 |
Why?
| | Checkpoint Kinase 2 | 2 | 2016 | 29 | 0.250 |
Why?
| | United States | 7 | 2024 | 14660 | 0.250 |
Why?
| | Surgical Wound Infection | 1 | 2009 | 302 | 0.240 |
Why?
| | Vaginal Neoplasms | 2 | 2016 | 18 | 0.240 |
Why?
| | Survival Analysis | 5 | 2017 | 1319 | 0.240 |
Why?
| | Obesity, Morbid | 1 | 2009 | 258 | 0.230 |
Why?
| | Anisotropy | 3 | 2020 | 79 | 0.230 |
Why?
| | Drug Approval | 1 | 2024 | 87 | 0.220 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 207 | 0.210 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2023 | 19 | 0.200 |
Why?
| | Medicare | 2 | 2020 | 747 | 0.200 |
Why?
| | Neoplasm Grading | 7 | 2019 | 306 | 0.190 |
Why?
| | Lewy Body Disease | 1 | 2022 | 29 | 0.190 |
Why?
| | DNA Methylation | 2 | 2022 | 644 | 0.190 |
Why?
| | ras Proteins | 2 | 2015 | 151 | 0.190 |
Why?
| | Transforming Growth Factor beta | 2 | 2016 | 480 | 0.190 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1731 | 0.190 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 104 | 0.190 |
Why?
| | Case-Control Studies | 6 | 2017 | 3537 | 0.180 |
Why?
| | Endometriosis | 1 | 2022 | 50 | 0.180 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2020 | 153 | 0.180 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 51 | 0.180 |
Why?
| | Sleep Wake Disorders | 2 | 2023 | 283 | 0.180 |
Why?
| | Computing Methodologies | 1 | 2020 | 3 | 0.180 |
Why?
| | Thrombocytosis | 2 | 2014 | 6 | 0.180 |
Why?
| | Leydig Cell Tumor | 1 | 2020 | 8 | 0.170 |
Why?
| | Benzamides | 1 | 2021 | 217 | 0.170 |
Why?
| | Hyperandrogenism | 1 | 2020 | 21 | 0.170 |
Why?
| | Population Surveillance | 3 | 2020 | 470 | 0.170 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2016 | 429 | 0.170 |
Why?
| | Diffusion | 1 | 2020 | 119 | 0.160 |
Why?
| | Optical Imaging | 1 | 2020 | 61 | 0.160 |
Why?
| | Retrospective Studies | 13 | 2020 | 15564 | 0.160 |
Why?
| | Genome-Wide Association Study | 6 | 2022 | 1434 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 2 | 2015 | 646 | 0.160 |
Why?
| | Cell Line, Tumor | 4 | 2016 | 3399 | 0.160 |
Why?
| | Fitness Trackers | 1 | 2019 | 12 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 783 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 217 | 0.150 |
Why?
| | Risk Reduction Behavior | 2 | 2018 | 218 | 0.150 |
Why?
| | Early Ambulation | 1 | 2019 | 24 | 0.150 |
Why?
| | Dementia | 1 | 2022 | 252 | 0.150 |
Why?
| | Monomeric GTP-Binding Proteins | 1 | 2018 | 11 | 0.150 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2018 | 25 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 189 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 226 | 0.140 |
Why?
| | Carcinoma in Situ | 2 | 2016 | 49 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 584 | 0.140 |
Why?
| | Regression Analysis | 1 | 2020 | 1024 | 0.140 |
Why?
| | A Kinase Anchor Proteins | 1 | 2018 | 72 | 0.140 |
Why?
| | Enzyme Multiplied Immunoassay Technique | 1 | 2017 | 2 | 0.140 |
Why?
| | Cadherins | 1 | 2019 | 205 | 0.140 |
Why?
| | Postoperative Care | 1 | 2019 | 257 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1455 | 0.130 |
Why?
| | Genetic Counseling | 1 | 2017 | 76 | 0.130 |
Why?
| | Remission Induction | 1 | 2017 | 287 | 0.130 |
Why?
| | Salpingectomy | 1 | 2016 | 13 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2022 | 491 | 0.130 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2016 | 59 | 0.130 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 765 | 0.130 |
Why?
| | Lymphocyte Activation | 1 | 2020 | 1150 | 0.130 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2016 | 45 | 0.120 |
Why?
| | Extracellular Matrix Proteins | 2 | 2015 | 152 | 0.120 |
Why?
| | Antigens, CD | 1 | 2019 | 522 | 0.120 |
Why?
| | Los Angeles | 2 | 2018 | 76 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1043 | 0.120 |
Why?
| | Cohort Studies | 6 | 2016 | 5718 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 390 | 0.120 |
Why?
| | Cyclin E | 1 | 2015 | 25 | 0.120 |
Why?
| | Genotype | 6 | 2018 | 1919 | 0.120 |
Why?
| | Gonadotropins | 1 | 2014 | 40 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2015 | 56 | 0.110 |
Why?
| | SEER Program | 1 | 2015 | 218 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 2015 | 59 | 0.110 |
Why?
| | Lymph Node Excision | 1 | 2016 | 170 | 0.110 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 190 | 0.110 |
Why?
| | Myofibroblasts | 1 | 2016 | 125 | 0.110 |
Why?
| | Corpus Callosum | 1 | 2014 | 70 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 327 | 0.110 |
Why?
| | Early Detection of Cancer | 3 | 2021 | 419 | 0.110 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 51 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2018 | 279 | 0.110 |
Why?
| | Promoter Regions, Genetic | 2 | 2010 | 1250 | 0.110 |
Why?
| | Interleukin-1alpha | 1 | 2013 | 58 | 0.100 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 137 | 0.100 |
Why?
| | Heterozygote | 4 | 2016 | 292 | 0.100 |
Why?
| | Cognitive Dysfunction | 1 | 2018 | 385 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1208 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2017 | 650 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2021 | 10764 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2016 | 492 | 0.100 |
Why?
| | Time Factors | 3 | 2021 | 6792 | 0.100 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 304 | 0.100 |
Why?
| | Brain Mapping | 1 | 2016 | 504 | 0.100 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 234 | 0.100 |
Why?
| | Cell Adhesion Molecules | 1 | 2013 | 181 | 0.100 |
Why?
| | Adenocarcinoma | 2 | 2011 | 936 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2012 | 25 | 0.100 |
Why?
| | Health Care Reform | 1 | 2013 | 102 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2016 | 1396 | 0.090 |
Why?
| | Endometrial Hyperplasia | 1 | 2011 | 8 | 0.090 |
Why?
| | Terminal Care | 1 | 2015 | 224 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1998 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2016 | 5115 | 0.090 |
Why?
| | Chromosomes, Human | 1 | 2011 | 44 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 78 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3566 | 0.090 |
Why?
| | Executive Function | 1 | 2016 | 448 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5749 | 0.090 |
Why?
| | Male | 9 | 2021 | 67361 | 0.090 |
Why?
| | Fibroblasts | 1 | 2016 | 989 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2016 | 1031 | 0.080 |
Why?
| | Mass Screening | 2 | 2010 | 1262 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2016 | 343 | 0.080 |
Why?
| | MutL Protein Homolog 1 | 1 | 2010 | 12 | 0.080 |
Why?
| | Genetic Association Studies | 3 | 2018 | 376 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2014 | 778 | 0.080 |
Why?
| | Sleep | 3 | 2023 | 751 | 0.080 |
Why?
| | Mammography | 2 | 2021 | 151 | 0.080 |
Why?
| | Microsatellite Instability | 1 | 2010 | 42 | 0.080 |
Why?
| | NF-kappa B | 1 | 2013 | 691 | 0.080 |
Why?
| | Leiomyomatosis | 1 | 2009 | 6 | 0.080 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 436 | 0.080 |
Why?
| | Suction | 1 | 2009 | 34 | 0.080 |
Why?
| | Incidence | 4 | 2021 | 2788 | 0.080 |
Why?
| | Signal Transduction | 4 | 2016 | 5065 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 916 | 0.070 |
Why?
| | Artifacts | 1 | 2009 | 129 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 81 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1059 | 0.070 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2009 | 80 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2016 | 1980 | 0.070 |
Why?
| | Alleles | 1 | 2011 | 888 | 0.070 |
Why?
| | Ovary | 2 | 2020 | 221 | 0.070 |
Why?
| | Conization | 1 | 2007 | 1 | 0.070 |
Why?
| | Registries | 1 | 2015 | 2015 | 0.070 |
Why?
| | Blood Vessels | 1 | 2009 | 187 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2007 | 63 | 0.070 |
Why?
| | Risk | 3 | 2016 | 904 | 0.070 |
Why?
| | Pseudogenes | 1 | 2006 | 18 | 0.060 |
Why?
| | Healthcare Disparities | 1 | 2013 | 649 | 0.060 |
Why?
| | Fertility | 1 | 2007 | 159 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 1697 | 0.060 |
Why?
| | Genes, Tumor Suppressor | 1 | 2005 | 86 | 0.060 |
Why?
| | Lymphoma | 1 | 2006 | 206 | 0.060 |
Why?
| | Quantitative Trait Loci | 2 | 2018 | 381 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 891 | 0.060 |
Why?
| | Laparoscopy | 1 | 2009 | 464 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1162 | 0.060 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 254 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 697 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 365 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2016 | 953 | 0.050 |
Why?
| | Aging | 1 | 2014 | 1861 | 0.050 |
Why?
| | Leukemia | 1 | 2006 | 238 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2019 | 507 | 0.050 |
Why?
| | Genetic Loci | 2 | 2015 | 288 | 0.050 |
Why?
| | Immunoenzyme Techniques | 2 | 2016 | 219 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 973 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2016 | 2831 | 0.050 |
Why?
| | Gene Expression | 1 | 2008 | 1499 | 0.050 |
Why?
| | Age Factors | 1 | 2010 | 3290 | 0.050 |
Why?
| | Muscle Hypertonia | 1 | 2022 | 8 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1942 | 0.050 |
Why?
| | Transcriptome | 2 | 2022 | 971 | 0.050 |
Why?
| | Linear Models | 2 | 2015 | 845 | 0.050 |
Why?
| | Algorithms | 1 | 2010 | 1686 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1568 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 267 | 0.050 |
Why?
| | Chromatin Immunoprecipitation | 2 | 2016 | 138 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2016 | 1483 | 0.040 |
Why?
| | Virilism | 1 | 2020 | 7 | 0.040 |
Why?
| | Sleep Deprivation | 1 | 2023 | 174 | 0.040 |
Why?
| | Prospective Studies | 3 | 2019 | 7583 | 0.040 |
Why?
| | Neuropsychological Tests | 2 | 2016 | 1054 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 13126 | 0.040 |
Why?
| | Cell Movement | 2 | 2016 | 969 | 0.040 |
Why?
| | California | 1 | 2021 | 424 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2005 | 658 | 0.040 |
Why?
| | Mastectomy | 1 | 2020 | 136 | 0.040 |
Why?
| | Ribonucleoproteins, Small Nucleolar | 1 | 2019 | 4 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2016 | 2473 | 0.040 |
Why?
| | Fanconi Anemia Complementation Group N Protein | 1 | 2016 | 5 | 0.030 |
Why?
| | Testosterone | 1 | 2020 | 401 | 0.030 |
Why?
| | Apoptosis | 2 | 2016 | 2548 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 751 | 0.030 |
Why?
| | Receptors, Lysosphingolipid | 1 | 2016 | 15 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1347 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2018 | 257 | 0.030 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2016 | 85 | 0.030 |
Why?
| | Sphingosine | 1 | 2016 | 46 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 97 | 0.030 |
Why?
| | Lysophospholipids | 1 | 2016 | 80 | 0.030 |
Why?
| | Gene Frequency | 1 | 2016 | 520 | 0.030 |
Why?
| | Apathy | 1 | 2015 | 7 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2750 | 0.030 |
Why?
| | Aurora Kinase A | 1 | 2015 | 56 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 286 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 386 | 0.030 |
Why?
| | E2F Transcription Factors | 1 | 2015 | 60 | 0.030 |
Why?
| | Oxazoles | 1 | 2015 | 37 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2015 | 142 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2015 | 103 | 0.030 |
Why?
| | Mammary Glands, Human | 1 | 2015 | 64 | 0.030 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2015 | 113 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 350 | 0.030 |
Why?
| | Thiazoles | 1 | 2015 | 123 | 0.030 |
Why?
| | Nucleotides | 1 | 2015 | 124 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3199 | 0.030 |
Why?
| | Random Allocation | 1 | 2015 | 353 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2021 | 1036 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 140 | 0.030 |
Why?
| | Genetic Markers | 1 | 2014 | 344 | 0.030 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2015 | 132 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 2015 | 195 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2013 | 116 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2015 | 145 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 387 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 400 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2016 | 255 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 518 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2015 | 217 | 0.030 |
Why?
| | Blotting, Western | 1 | 2016 | 1225 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 692 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2020 | 4194 | 0.020 |
Why?
| | Attention | 1 | 2016 | 435 | 0.020 |
Why?
| | Vagina | 1 | 2014 | 186 | 0.020 |
Why?
| | Hospice Care | 1 | 2015 | 201 | 0.020 |
Why?
| | Advance Care Planning | 1 | 2015 | 203 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2015 | 864 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 777 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1756 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2011 | 54 | 0.020 |
Why?
| | Premenopause | 1 | 2011 | 131 | 0.020 |
Why?
| | Pyridines | 1 | 2015 | 505 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2011 | 72 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2015 | 611 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4158 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2015 | 488 | 0.020 |
Why?
| | Health Personnel | 1 | 2017 | 698 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2030 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2011 | 145 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2011 | 169 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 397 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2060 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2999 | 0.020 |
Why?
| | Carboplatin | 1 | 2009 | 143 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1453 | 0.020 |
Why?
| | Mice | 2 | 2016 | 17731 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1513 | 0.020 |
Why?
| | Brachytherapy | 1 | 2009 | 119 | 0.020 |
Why?
| | Paclitaxel | 1 | 2009 | 227 | 0.020 |
Why?
| | Parity | 1 | 2007 | 126 | 0.020 |
Why?
| | Medical Records | 1 | 2007 | 172 | 0.020 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2006 | 45 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2006 | 95 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1235 | 0.020 |
Why?
| | Osteosarcoma | 1 | 2006 | 75 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 87 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2005 | 15 | 0.010 |
Why?
| | Exons | 1 | 2006 | 349 | 0.010 |
Why?
| | Pregnancy Outcome | 1 | 2007 | 409 | 0.010 |
Why?
| | Reoperation | 1 | 2007 | 565 | 0.010 |
Why?
| | CpG Islands | 1 | 2005 | 159 | 0.010 |
Why?
| | Methylation | 1 | 2005 | 231 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 817 | 0.010 |
Why?
| | Mediator Complex | 1 | 2005 | 61 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2015 | 2050 | 0.010 |
Why?
| | Bone Neoplasms | 1 | 2006 | 248 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1260 | 0.010 |
Why?
| | Animals | 2 | 2016 | 36768 | 0.010 |
Why?
| | Histones | 1 | 2005 | 635 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2006 | 619 | 0.010 |
Why?
| | Pregnancy | 1 | 2007 | 6731 | 0.010 |
Why?
|
|
Walsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|